Scaling Competitive Biopharma in Europe
How is new momentum in European biopharma evolving?
Europe’s emerging biopharma companies are operating in a markedly different capital environment than even two years ago. Geopolitical tensions, pricing constraints and fragmented regulation are tightening access to funding and raising the bar for building globally competitive assets. Despite producing world-class research and innovation, Europe has lost much of its global share in biopharma; it now trails both the US and China in the launch of new medicines and in pipeline growth.
New policy reforms such as the European Biotech Act and regulatory uncertainty in the US are impacting capital flows and shifting focus towards Europe. Biotech companies and their backers must find ways to contend with the complex regulatory and data requirements. How realistic is it for biotechs advancing clinical assets to secure venture funding under current conditions? Can they do so without having to tap US markets? What defines an investible biotech and what levels of risk will investors tolerate? Will European R&D lose out to faster-moving rivals in China?
This briefing, hosted by the Financial Times in partnership with Syneos Health, will bring together leading executives and investors to focus on what it takes to succeed in Europe’s launch environment. The discussions evaluate ways to sustain capital flows through launch and explore how to scale the next generation of globally competitive biopharma companies.
Key Discussion Points
Global Scalability
How do VCs evaluate the global scalability of European assets? How does launch sequencing factor into valuation expectations?
Mitigating Risk
How can a well-structured launch strategy help mitigate risk and influence access to capital and exit optionality?
European Opportunity
Can US regulatory instability and business uncertainty become Europe’s opportunity?
“Data from Syneos speakers was insightful and the real world experience of industry speakers provided some great context.”
Past event delegate
We’re Here To Help
Speaking Opportunities
Ailsa Matkevich
ailsa.matkevich@ft.com
Sponsorship Opportunities
Tim Powell
tim.powell@ft.com
Frequently Asked Questions